CS215008B2 - Method of gaining natural polar fractions with antipsoriatic activity - Google Patents
Method of gaining natural polar fractions with antipsoriatic activity Download PDFInfo
- Publication number
- CS215008B2 CS215008B2 CS794777A CS477779A CS215008B2 CS 215008 B2 CS215008 B2 CS 215008B2 CS 794777 A CS794777 A CS 794777A CS 477779 A CS477779 A CS 477779A CS 215008 B2 CS215008 B2 CS 215008B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- polypodium
- extraction
- solution
- rhizomes
- fraction
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 230000002682 anti-psoriatic effect Effects 0.000 title claims description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241001362840 Serpocaulon triseriale Species 0.000 claims abstract description 3
- 229940075984 polypodium leucotomos Drugs 0.000 claims abstract description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims abstract 3
- 239000000920 calcium hydroxide Substances 0.000 claims abstract 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims abstract 3
- 241001518143 Polypodium <fern> Species 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 7
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 241000196324 Embryophyta Species 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 241000487005 Phlebodium decumanum Species 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000012452 mother liquor Substances 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 235000012211 aluminium silicate Nutrition 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims 1
- 241000905957 Channa melasoma Species 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 230000002262 irrigation Effects 0.000 claims 1
- 238000003973 irrigation Methods 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920005990 polystyrene resin Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 abstract description 10
- 238000000746 purification Methods 0.000 abstract description 3
- 241000723185 Cyathea Species 0.000 abstract description 2
- 241000393483 Dryopteris crassirhizoma Species 0.000 abstract description 2
- 241000985694 Polypodiopsida Species 0.000 abstract description 2
- 241000244324 Polypodium aureum Species 0.000 abstract description 2
- 241000592274 Polypodium vulgare Species 0.000 abstract description 2
- 239000002798 polar solvent Substances 0.000 abstract 2
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000012454 non-polar solvent Substances 0.000 abstract 1
- 238000000638 solvent extraction Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 239000006194 liquid suspension Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 206010033898 parapsoriasis Diseases 0.000 description 2
- 230000008807 pathological lesion Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940030999 antipsoriatics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 230000004090 etiopathogenesis Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000030414 genetic transfer Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES471572A ES471572A1 (es) | 1978-07-07 | 1978-07-07 | Procedimiento de obtencion de fraccion polar natural con ac-tividad antipsoriatica |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS215008B2 true CS215008B2 (en) | 1982-06-25 |
Family
ID=8476458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS794777A CS215008B2 (en) | 1978-07-07 | 1979-07-06 | Method of gaining natural polar fractions with antipsoriatic activity |
Country Status (35)
| Country | Link |
|---|---|
| JP (1) | JPS6026376B2 (fr) |
| AR (1) | AR230188A1 (fr) |
| AT (1) | AT371715B (fr) |
| AU (1) | AU4876479A (fr) |
| BE (1) | BE874483A (fr) |
| CA (1) | CA1106285A (fr) |
| CH (1) | CH642085A5 (fr) |
| CS (1) | CS215008B2 (fr) |
| DD (1) | DD144719A5 (fr) |
| DE (1) | DE2900887A1 (fr) |
| DK (1) | DK180379A (fr) |
| EG (1) | EG14496A (fr) |
| ES (1) | ES471572A1 (fr) |
| FI (1) | FI792128A7 (fr) |
| FR (1) | FR2434819A1 (fr) |
| GB (1) | GB2024622B (fr) |
| GR (1) | GR65334B (fr) |
| HU (1) | HU179689B (fr) |
| IE (1) | IE48526B1 (fr) |
| IL (1) | IL57721A (fr) |
| IS (1) | IS2495A7 (fr) |
| IT (1) | IT7919807A0 (fr) |
| LU (1) | LU81464A1 (fr) |
| MA (1) | MA18512A1 (fr) |
| MX (1) | MX5596E (fr) |
| NL (1) | NL7905251A (fr) |
| NO (1) | NO792260L (fr) |
| NZ (1) | NZ190933A (fr) |
| OA (1) | OA06288A (fr) |
| PH (1) | PH14338A (fr) |
| PL (1) | PL124244B1 (fr) |
| PT (1) | PT69067A (fr) |
| RO (1) | RO76833A (fr) |
| SE (1) | SE7903762L (fr) |
| ZA (1) | ZA793398B (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES470204A1 (es) * | 1978-05-24 | 1979-01-01 | Conrad Ltd | Procedimiento de obtencion de terpenos naturales con activi-dad antipsoriatica |
| ES490293A0 (es) * | 1980-04-02 | 1981-04-16 | Conrad Ltd | Un procedimiento de obtencion de un extracto de las fraccio-nes polares de los helechos de la familia polypodiaceae. |
| NO150880C (no) * | 1981-06-01 | 1985-01-16 | Borregaard Ind | Nye aza-krone-etere og anvendelse derav |
| EP0364442B1 (fr) * | 1987-12-23 | 1993-03-03 | Psoricur Ltd. | Compositions therapeutiques anti-psoriasiques |
| EP0503208A1 (fr) * | 1991-03-08 | 1992-09-16 | Maracuyama International, S.A. | Procédé d'obtention d'un extrait naturel soluble dans l'eau de feuilles et/ou de rhizomes de différentes fougères possédant une activité immunologique |
| JPH0633820U (ja) * | 1992-10-13 | 1994-05-06 | マルヤス機械株式会社 | ローラコンベア |
| ATE222112T1 (de) * | 1994-05-06 | 2002-08-15 | Esp Farmaceuticas Centrum Sa | Pharmazeutische zusammensetzung enthaltend farnextrakt(e) zur behandlung von neurodegenerativen krankheiten. |
| ES2068163B1 (es) * | 1994-05-06 | 1995-09-01 | Esp Farmaceuticas Centrum Sa | Procedimiento de obtencion de un extracto vegetal con actividad en el tratamiento de disfunciones cognitivas y/o neuroinmunes. |
| ES2137900B1 (es) * | 1998-06-02 | 2000-08-16 | Helsint S A L | Empleo de formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum como complemento nutricional en el tratamiento del sindrome caquectico en pacientes oncologicos. |
| WO1999006058A1 (fr) * | 1997-07-30 | 1999-02-11 | Helsint, S.A.L. | Fractions hydrosolubles de phlebodium decumanum et leur utilisation en tant que complement nutritionnel chez des patients souffrant du sida et de cancer |
| ES2124675B1 (es) * | 1997-07-30 | 1999-10-01 | Helsint S A L | "formulaciones a base de una fraccion hidrosoluble de phlebodium decumanum, y su uso en el tratamiento del sindrome caquectico en enfermos de sida". |
| FR2863163B1 (fr) * | 2003-12-04 | 2006-02-24 | Oreal | Composition, notamment cosmetique, comprenant des extraits de fougere et de nacre |
| FR2876032B1 (fr) * | 2004-10-05 | 2008-10-31 | Greentech Sa Sa | Utilisation d'extraits de fougeres dans des preparations cosmetiques ou dermatologiques |
| US20060246115A1 (en) * | 2005-03-04 | 2006-11-02 | Ricardo Rueda | Nutritional products for ameliorating symptoms of rheumatoid arthritis |
| USD554789S1 (en) * | 2006-09-14 | 2007-11-06 | Huo-Tu Huang | Table lamp |
| AT515350A1 (de) * | 2014-02-10 | 2015-08-15 | Christoph Dipl Ing Brandstätter | Verfahren zur Herstellung eines Konzentrats eines Holzschutzmittels, damit hergestelltes Konzentrat und Verfahren zur Behandlung von Holz |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB256768A (en) * | 1925-07-17 | 1926-08-19 | Francesco Fumarola | Process for extraction of the active biological principles from the ether extract of male fern |
| US3395223A (en) * | 1965-05-13 | 1968-07-30 | Carter Wallace | Fern extract for treating gastric ulcers |
| FR2395266A1 (fr) * | 1977-06-23 | 1979-01-19 | Suffren Ste Parti Brevets | -lactone monomeres et leurs polymeres, sels et derives, utilisables notamment comme colorants, adjuvants de tannage et medicaments |
| JPS5464870A (en) * | 1977-10-21 | 1979-05-25 | Gte Laboratories Inc | Solid state microwave power supply for electrodeless light source |
-
1978
- 1978-07-07 ES ES471572A patent/ES471572A1/es not_active Expired
- 1978-12-27 AR AR274971A patent/AR230188A1/es active
- 1978-12-28 GR GR57991A patent/GR65334B/el unknown
-
1979
- 1979-01-11 DE DE19792900887 patent/DE2900887A1/de not_active Withdrawn
- 1979-01-12 PT PT69067A patent/PT69067A/pt unknown
- 1979-01-29 FR FR7902226A patent/FR2434819A1/fr active Granted
- 1979-02-01 IT IT7919807A patent/IT7919807A0/it unknown
- 1979-02-27 BE BE193723A patent/BE874483A/fr not_active IP Right Cessation
- 1979-03-28 CA CA324,314A patent/CA1106285A/fr not_active Expired
- 1979-04-27 SE SE7903762A patent/SE7903762L/xx unknown
- 1979-05-02 DK DK180379A patent/DK180379A/da not_active Application Discontinuation
- 1979-05-22 CH CH477779A patent/CH642085A5/de not_active IP Right Cessation
- 1979-05-24 JP JP54064871A patent/JPS6026376B2/ja not_active Expired
- 1979-05-24 GB GB7918174A patent/GB2024622B/en not_active Expired
- 1979-05-29 MX MX798029U patent/MX5596E/es unknown
- 1979-07-04 IL IL57721A patent/IL57721A/xx unknown
- 1979-07-05 NL NL7905251A patent/NL7905251A/nl not_active Application Discontinuation
- 1979-07-05 LU LU81464A patent/LU81464A1/fr unknown
- 1979-07-05 FI FI792128A patent/FI792128A7/fi not_active Application Discontinuation
- 1979-07-05 IS IS2495A patent/IS2495A7/is unknown
- 1979-07-06 HU HU79CO371A patent/HU179689B/hu unknown
- 1979-07-06 AT AT0471479A patent/AT371715B/de not_active IP Right Cessation
- 1979-07-06 NZ NZ190933A patent/NZ190933A/xx unknown
- 1979-07-06 ZA ZA793398A patent/ZA793398B/xx unknown
- 1979-07-06 CS CS794777A patent/CS215008B2/cs unknown
- 1979-07-06 PL PL1979216905A patent/PL124244B1/pl unknown
- 1979-07-06 OA OA56841A patent/OA06288A/fr unknown
- 1979-07-06 MA MA18709A patent/MA18512A1/fr unknown
- 1979-07-06 NO NO792260A patent/NO792260L/no unknown
- 1979-07-07 EG EG415/79A patent/EG14496A/xx active
- 1979-07-07 RO RO7998089A patent/RO76833A/fr unknown
- 1979-07-09 DD DD79214207A patent/DD144719A5/de unknown
- 1979-07-09 AU AU48764/79A patent/AU4876479A/en not_active Abandoned
- 1979-07-09 PH PH22755A patent/PH14338A/en unknown
- 1979-08-08 IE IE1274/79A patent/IE48526B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS215008B2 (en) | Method of gaining natural polar fractions with antipsoriatic activity | |
| US4985252A (en) | Medication, dietetic product and hygienic product in the form of a powered composition obtained by adsorption of active ingredients on a rapidly dissolving sugar and process for obtaining said composition | |
| WO1987003480A2 (fr) | Medicament a effet anti-tumoral contenant de l'hexadecylphosphocholine | |
| CN111148729A (zh) | 苯烯莫德的晶型及其用途与制备方法 | |
| DE69411981T2 (de) | Haarregenerierendes Mittel | |
| EP0503208A1 (fr) | Procédé d'obtention d'un extrait naturel soluble dans l'eau de feuilles et/ou de rhizomes de différentes fougères possédant une activité immunologique | |
| LU80739A1 (de) | Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor | |
| CN111056935A (zh) | 去芳化异戊烯基酰基间苯三酚类衍生物及其药物组合物和应用 | |
| JP2002543125A (ja) | リンパ増殖性および自己免疫症状の治療のための、ボスウェリアセラータ（Ｂｏｓｗｅｌｌｉａｓｅｒｒａｔａ）ゴム樹脂由来ボスウェリン酸の組成物 | |
| RU2137490C1 (ru) | Иммуностимулирующее средство эстифан и способ его получения | |
| CA1122589A (fr) | Procede pour l'obtention de terpenes naturels, antipsoriasiques | |
| US6586021B2 (en) | Method for extraction and purification of biologically useful molecules from a mangrove plant Salvadora persica L | |
| DE69626548T2 (de) | Macrocyclische verbindungen die aus kohlensuboxi-gruppen besteht | |
| Krieger et al. | Metabolism of 2, 2-dimethyl-2, 3-dihydrobenzofuranyl-7 N-dimethoxyphosphinothioyl-N-methylcarbamate in the house fly, rat, and mouse | |
| GB2075834A (en) | Arthritis treatment with fern extracts | |
| CA2087600C (fr) | Agent chimiotherapique neoplasique d'origine vegetale, a haute selectivite et a toxicite tres reduite; methode de preparation | |
| NZ221527A (en) | Scymnol sulphates | |
| Ajibade et al. | Histopathological and toxicological effects of crude saponin extract from Phyllanthus niruri, L (Syn. P. franternus. Webster) on organs in animal studies | |
| DE69717961T2 (de) | Verwendung eines flavonoid enthaltenden extraktes der planze euphorbia prostrata zur herstellung eines medikamentes zur behandlung von anoraktalen oder kolonbeschwerden | |
| JP2003113088A (ja) | 発ガンプロモーター抑制剤及びそれを含有する組成物 | |
| KR19980045814A (ko) | 사이트로스테디엔올을 보체 활성 조절제로 사용하는 용도 및 그의 제조방법 | |
| Coulston et al. | The relationship of psyllium seed and various fractions of the seed to kidney pigmentation | |
| AU2005202105B2 (en) | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora Persica L. | |
| JPH0228114A (ja) | 腎炎治療薬 | |
| CS221521B2 (en) | Method of making the derivatives of the 1,4-dioxanaphtalene |